GSK’s (GSK) niraparib was granted FDA orphan designation as a treatment of malignant glioma, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- ViiV Healthcare announces 96-week data from PASO DOBLE on Dovato
- GSK’s Asthma Study Update: Potential Market Impacts
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- GSK CEO downplays role in leucovorin FDA effort, STAT reports
- GSK’s RSV Vaccine Study Update: Promising Developments for Older Adults